Revolutionizing Women’s Health: Harvard Apparatus’s Breakthrough in Uterine Regeneration and Fertility Restoration
Harvard Apparatus Regenerative Technology, a clinical-stage biotechnology company, has announced a new collaboration with Dr. Hugh Taylor, chair of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine. This partnership, formalized through a Sponsored Research Agreement, aims to tackle a significant women’s health issue: intrauterine adhesions (IUAs). These adhesions, leading to infertility and menstrual […]
RoslinCT Unveils CRISPR: A Medical Revolution Begins
RoslinCT, a renowned cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), has announced a significant advancement in the field of medical science. They will be manufacturing the world’s first CRISPR-based therapy, exa-cel, for Vertex Pharmaceuticals Inc. This development follows an extensive collaboration between the two entities. Key Highlights: About RoslinCT: RoslinCT has a […]
BrainStorm Cell Therapeutics Announces Key FDA Meeting for ALS Treatment
BrainStorm Cell Therapeutics Inc., a prominent developer of adult stem cell therapies for neurodegenerative diseases, has announced a significant development in their pursuit of treating amyotrophic lateral sclerosis (ALS). The company has secured an in-person meeting with the U.S. Food & Drug Administration (FDA), scheduled for December 6, 2023. This meeting is a critical step […]
UP421: Revolutionizing Diabetes Treatment Without Immunosuppression
Uppsala University Hospital and Sana Biotechnology recently announced a groundbreaking development in diabetes treatment. They have received authorization from the Swedish Medical Products Agency for a first-in-human clinical trial of UP421, a novel islet cell therapy for type 1 diabetes. This treatment, developed using Sana’s innovative hypoimmune (HIP) technology, aims to transplant functional islet cells […]
Revolutionizing Stem Cell Research: ACROBiosystems’ DLL4
ACROBiosystems, a pivotal player in the pharmaceutical industry, recently announced the launch of its GMP grade DLL4, a significant advancement in the field of stem cell research and biologics manufacturing. DLL4, or Delta-like Ligand 4, is a recombinant, soluble protein now available in a GMP (Good Manufacturing Practice) compliant form. This launch marks a considerable […]
Synthetic Embryos: Ethical Dilemma or Medical Breakthrough?
In a groundbreaking exploration of the boundaries of life and technology, scientists at the Weizmann Institute of Science in Israel have made a significant leap forward in the field of embryology. The research team, led by Jacob Hanna, has successfully reprogrammed stem cells to form structures strikingly similar to human embryos, a feat that could […]
Garuda Wins Big: Revolutionizing Stem Cell Therapy
Garuda Therapeutics has been honored with the prestigious title of “Overall Cell Biology Company of the Year” by BioTech Breakthrough, an independent organization that recognizes top performers in the life sciences and biotechnology sectors. This accolade was awarded to Garuda for their innovative approach to creating off-the-shelf hematopoietic stem cell (HSC) therapies. These therapies are […]
Avid Bioservices Partners with California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs
Avid Bioservices, a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it has partnered with the California Institute for Regenerative Medicine (CIRM), California’s stem cell agency, to provide contract development and manufacturing (CDMO) services for cell and gene therapy (CGT) programs funded by CIRM. Through this partnership, Avid will make its CGMP […]
Tract Bio Unveils Key to CF Lung Inflammation
Tract Bio, a biotechnology company focused on developing therapies for cancer and inflammatory diseases, has recently announced a significant publication in the American Journal of Respiratory and Critical Care Medicine. The publication details their research on stem cell variants that contribute to chronic lung inflammation in cystic fibrosis patients treated with CFTR modulators. Key Highlights […]
Revolutionary ExoPTEN Therapy: FDA’s New Hope for Spinal Injuries
NurExone Biologic Inc., a leading biotechnology company, has recently achieved a significant milestone in the development of treatments for acute spinal cord injuries. The U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) to the company’s innovative ExoPTEN therapy. This designation is crucial for conditions like acute spinal cord injury, where effective treatments […]